Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
USD 49.0
(0.0%)
USD 49.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.58 Billion EUR | 10.85% |
| 2022 | 1.43 Billion EUR | 91.51% |
| 2021 | 747.61 Million EUR | -14.35% |
| 2020 | 872.82 Million EUR | -9.0% |
| 2019 | 959.16 Million EUR | 55.78% |
| 2018 | 615.71 Million EUR | 51.13% |
| 2017 | 407.4 Million EUR | 75.16% |
| 2016 | 232.59 Million EUR | 51.1% |
| 2015 | 153.92 Million EUR | -36.61% |
| 2014 | 242.83 Million EUR | -6.87% |
| 2013 | 260.74 Million EUR | 67.09% |
| 2012 | 156.04 Million EUR | 34.41% |
| 2011 | 116.09 Million EUR | -0.67% |
| 2010 | 116.87 Million EUR | 5.05% |
| 2009 | 111.26 Million EUR | -36.22% |
| 2008 | 174.45 Million EUR | -2.53% |
| 2007 | 178.98 Million EUR | 44.64% |
| 2006 | 123.74 Million EUR | 1024.05% |
| 2005 | 11 Million EUR | 114.63% |
| 2004 | -75.23 Million EUR | -452.01% |
| 2003 | 21.37 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.43 Billion EUR | -9.3% |
| 2024 Q2 | 1.47 Billion EUR | -110.44% |
| 2023 FY | 1.58 Billion EUR | 10.85% |
| 2023 Q1 | 1.34 Billion EUR | -5.74% |
| 2023 Q2 | 1.33 Billion EUR | -1.0% |
| 2023 Q3 | 1.51 Billion EUR | 13.28% |
| 2023 Q4 | 1.58 Billion EUR | 4.86% |
| 2022 Q3 | 1.35 Billion EUR | -6.91% |
| 2022 FY | 1.43 Billion EUR | 91.51% |
| 2022 Q4 | 1.43 Billion EUR | 5.77% |
| 2022 Q1 | 1.4 Billion EUR | 88.53% |
| 2022 Q2 | 1.45 Billion EUR | 3.17% |
| 2021 Q3 | 724.42 Million EUR | -17.27% |
| 2021 Q4 | 747.61 Million EUR | 3.2% |
| 2021 FY | 747.61 Million EUR | -14.35% |
| 2021 Q1 | 861.29 Million EUR | -1.32% |
| 2021 Q2 | 875.69 Million EUR | 1.67% |
| 2020 Q3 | 2.25 Billion EUR | 5.94% |
| 2020 Q4 | 872.82 Million EUR | -61.25% |
| 2020 FY | 872.82 Million EUR | -9.0% |
| 2020 Q1 | 2.02 Billion EUR | 111.59% |
| 2020 Q2 | 2.12 Billion EUR | 4.77% |
| 2019 FY | 959.16 Million EUR | 55.78% |
| 2019 Q3 | 2.12 Billion EUR | 234.89% |
| 2019 Q2 | 635.67 Million EUR | -54.43% |
| 2019 Q1 | 1.39 Billion EUR | 126.57% |
| 2019 Q4 | 959.16 Million EUR | -54.94% |
| 2018 FY | 615.71 Million EUR | 51.13% |
| 2018 Q3 | 1.26 Billion EUR | -2.37% |
| 2018 Q4 | 615.71 Million EUR | -51.32% |
| 2018 Q2 | 1.29 Billion EUR | 1.79% |
| 2018 Q1 | 1.27 Billion EUR | 212.44% |
| 2017 Q2 | 832.88 Million EUR | 34.8% |
| 2017 FY | 407.4 Million EUR | 75.16% |
| 2017 Q4 | 407.4 Million EUR | -64.71% |
| 2017 Q3 | 1.15 Billion EUR | 38.6% |
| 2017 Q1 | 617.85 Million EUR | 165.64% |
| 2016 FY | 232.59 Million EUR | 51.1% |
| 2016 Q4 | 232.59 Million EUR | -57.59% |
| 2016 Q3 | 548.39 Million EUR | -4.89% |
| 2016 Q2 | 576.58 Million EUR | -1.79% |
| 2016 Q1 | 587.11 Million EUR | 281.42% |
| 2015 Q2 | 613.39 Million EUR | 0.32% |
| 2015 Q4 | 153.92 Million EUR | -74.06% |
| 2015 Q3 | 593.4 Million EUR | -3.26% |
| 2015 Q1 | 611.41 Million EUR | 151.78% |
| 2015 FY | 153.92 Million EUR | -36.61% |
| 2014 Q1 | 552.7 Million EUR | 111.97% |
| 2014 FY | 242.83 Million EUR | -6.87% |
| 2014 Q4 | 242.83 Million EUR | -63.26% |
| 2014 Q3 | 660.99 Million EUR | 22.8% |
| 2014 Q2 | 538.28 Million EUR | -2.61% |
| 2013 Q4 | 260.74 Million EUR | -44.77% |
| 2013 Q2 | 392.68 Million EUR | 102.06% |
| 2013 Q1 | 194.34 Million EUR | 24.54% |
| 2013 FY | 260.74 Million EUR | 67.09% |
| 2013 Q3 | 472.1 Million EUR | 20.22% |
| 2012 Q1 | 55.6 Million EUR | -52.11% |
| 2012 Q2 | 69.61 Million EUR | 25.21% |
| 2012 Q3 | 47.89 Million EUR | -31.2% |
| 2012 FY | 156.04 Million EUR | 34.41% |
| 2012 Q4 | 156.04 Million EUR | 225.82% |
| 2011 Q3 | 193.59 Million EUR | 747.24% |
| 2011 Q4 | 116.09 Million EUR | -40.03% |
| 2011 Q1 | 161.3 Million EUR | 38.01% |
| 2011 Q2 | -29.91 Million EUR | -118.54% |
| 2011 FY | 116.09 Million EUR | -0.67% |
| 2010 Q1 | 3.74 Million EUR | -96.63% |
| 2010 FY | 116.87 Million EUR | 5.05% |
| 2010 Q2 | 93 Million EUR | 2382.15% |
| 2010 Q3 | 91.13 Million EUR | -2.01% |
| 2010 Q4 | 116.87 Million EUR | 28.25% |
| 2009 Q4 | 111.26 Million EUR | 0.0% |
| 2009 FY | 111.26 Million EUR | -36.22% |
| 2008 FY | 174.45 Million EUR | -2.53% |
| 2007 FY | 178.98 Million EUR | 44.64% |
| 2006 FY | 123.74 Million EUR | 1024.05% |
| 2005 FY | 11 Million EUR | 114.63% |
| 2004 FY | -75.23 Million EUR | -452.01% |
| 2003 FY | 21.37 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 93.024% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 94.71% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 199.564% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | -9910.647% |
| Novartis AG | 12.95 Billion USD | 87.749% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | 1035.223% |